Pliant Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.85 Insider Own8.96% Shs Outstand36.12M Perf Week11.36%
Market Cap322.18M Forward P/E- EPS next Y-3.61 Insider Trans0.00% Shs Float32.93M Perf Month31.84%
Income-102.50M PEG- EPS next Q-0.85 Inst Own88.90% Short Float6.33% Perf Quarter15.11%
Sales6.60M P/S48.81 EPS this Y-39.40% Inst Trans3.18% Short Ratio7.03 Perf Half Y-39.50%
Book/sh4.81 P/B1.77 EPS next Y-8.80% ROA-45.20% Target Price38.00 Perf Year-67.96%
Cash/sh4.72 P/C1.81 EPS next 5Y- ROE-49.00% 52W Range3.96 - 28.80 Perf YTD-36.81%
Dividend- P/FCF- EPS past 5Y- ROI-47.30% 52W High-70.38% Beta-
Dividend %- Quick Ratio10.10 Sales past 5Y- Gross Margin- 52W Low115.13% ATR0.68
Employees91 Current Ratio10.10 Sales Q/Q-45.50% Oper. Margin- RSI (14)64.59 Volatility7.72% 9.56%
OptionableYes Debt/Eq0.04 EPS Q/Q-21.30% Profit Margin- Rel Volume0.41 Prev Close8.12
ShortableYes LT Debt/Eq0.03 EarningsMay 09 AMC Payout- Avg Volume296.73K Price8.53
Recom1.70 SMA2015.12% SMA5036.28% SMA200-23.81% Volume122,787 Change5.05%
May-25-22Initiated Cantor Fitzgerald Overweight $28
Dec-10-21Initiated Oppenheimer Outperform $40
Nov-24-21Initiated RBC Capital Mkts Outperform $38
Nov-03-21Initiated H.C. Wainwright Buy $45
Apr-20-21Initiated BTIG Research Buy $51
Apr-05-21Initiated Citigroup Buy $52
Jun-29-20Initiated Piper Sandler Overweight $50
Jun-29-20Initiated Needham Buy $40
Jun-29-20Initiated Cowen Outperform
Jun-29-20Initiated Citigroup Buy $40
Jun-24-22 08:00AM  
Jun-22-22 08:00AM  
Jun-16-22 08:00AM  
Jun-15-22 04:01PM  
May-18-22 11:15AM  
May-11-22 08:00AM  
May-09-22 05:25PM  
May-05-22 06:25PM  
May-03-22 08:00AM  
May-02-22 08:00AM  
Apr-13-22 02:24PM  
Apr-08-22 08:44AM  
Apr-05-22 08:03AM  
Feb-28-22 07:43PM  
Feb-24-22 05:41PM  
Feb-07-22 12:10PM  
Jan-11-22 08:03AM  
Dec-21-21 08:06AM  
Dec-13-21 07:37PM  
Nov-30-21 05:24AM  
Nov-18-21 08:00AM  
Nov-10-21 10:32AM  
Nov-09-21 06:35PM  
Oct-07-21 08:06AM  
Sep-07-21 12:12PM  
Sep-03-21 04:10PM  
Sep-02-21 08:00AM  
Aug-11-21 06:44AM  
Aug-09-21 04:05PM  
Aug-03-21 08:00AM  
May-13-21 02:30AM  
May-10-21 04:21PM  
May-05-21 08:05AM  
Apr-05-21 08:00AM  
Mar-22-21 08:54AM  
Mar-16-21 04:05PM  
Feb-18-21 08:30AM  
Feb-17-21 09:00AM  
Feb-09-21 08:52AM  
Jan-12-21 08:00AM  
Jan-04-21 08:00AM  
Dec-11-20 12:54PM  
Dec-02-20 03:28AM  
Nov-19-20 08:00AM  
Nov-10-20 04:05PM  
Nov-09-20 08:00AM  
Oct-05-20 08:00AM  
Sep-24-20 08:00AM  
Sep-04-20 08:00AM  
Sep-03-20 12:28PM  
Aug-27-20 06:00AM  
Aug-11-20 04:05PM  
Jun-13-20 07:01AM  
Jun-05-20 04:05PM  
Jun-04-20 08:13AM  
Jun-03-20 03:54PM  
Jun-02-20 09:56PM  
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cummings Keith LamontChief Financial OfficerSep 03Option Exercise2.0820,00041,60067,621Sep 03 06:27 PM